Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | EIF4A3 | P38919 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.32 |
| ▸ | FABP3 | P05413 | 1/20 | 0.31 |
| ▸ | FABP4 | P15090 | 1/20 | 0.31 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.31 |
| ▸ | NAAA | Q02083 | 1/20 | 0.30 |
| ▸ | PDE2A | O00408 | 1/20 | 0.30 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.30 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.30 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14404558 | 0.91 | DPP4 (0.38) | DPP4EIF4A3ALOX15ALOX12FABP3 | |
| SCHEMBL22019113 | 0.87 | EIF4A3 (0.38) | DPP4EIF4A3ALOX15ALOX12FABP3 | |
| SCHEMBL27308803 | 0.83 | EIF4A3 (0.36) | EIF4A3ALOX15ALOX12 | |
| SCHEMBL13413598 | 0.82 | GRIN2D (0.39) | EIF4A3ALOX15ALOX12PDE2A | |
| SCHEMBL10552802 | 0.82 | EIF4A3 (0.35) | EIF4A3PDE2A | |
| SCHEMBL13592734 | 0.81 | DPP4 (0.37) | DPP4EIF4A3ADRB2ADRB1ADRB3 | |
| SCHEMBL16736709 | 0.79 | ALOX15 (0.42) | EIF4A3ALOX15ALOX12ADRB2ADRB1 | |
| SCHEMBL23731995 | 0.79 | TAAR1 (0.42) | — | |
| SCHEMBL9886089 | 0.79 | TAAR1 (0.50) | — | |
| SCHEMBL13319560 | 0.78 | EIF4A3 (0.41) | DPP4EIF4A3FABP3FABP4PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019118358-A1 | HEPATITIS B CAPSID ASSEMBLY MODULATORS | VenatoRx Pharmaceuticals, Inc. (US) | 2019-06-20 | — | — | WO | disclosed |
| US-8507723-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| US-20120322878-A1 | Polycationic Compounds And Uses Thereof | POLYMEDIX, INC. (US) | 2012-12-20 | — | — | US | disclosed |
| US-7893224-B2 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-02-22 | — | — | US | disclosed |
| US-7745662-B2 | Polycationic compounds and uses thereof | POLYMEDIX, INC. (US) | 2010-06-29 | — | — | US | disclosed |
| US-20090312531-A1 | OLIGNUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | US | disclosed |
| US-7632932-B2 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS, INC. (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | ALNYLAM PHARMACEUTICALS (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312531-A1 | OLIGNUCLEOTIDES COMPRISING A LIGAND TETHERED TO A MODIFIED OR NON-NATURAL NUCLEOBASE | DUT, NOP58, DPYD | DPP4 2435/4885EIF4A3 624/4885ALOX15 3219/4885 |
| US-20120322878-A1 | Polycationic Compounds And Uses Thereof | VEGFA, VHL, PGF | DPP4 1901/4885EIF4A3 1552/4885ALOX15 1107/4885 |
| US-20070054279-A1 | Oligonucleotides comprising a ligand tethered to a modified or non-natural nucleobase | DERA, NT5C3B, DUT | DPP4 1619/4885EIF4A3 871/4885ALOX15 3305/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.